Basit öğe kaydını göster

dc.contributor.authorSmith, Ian
dc.contributor.authorMauriac, Louis
dc.contributor.authorLang, Istvan
dc.contributor.authorForbes, John F.
dc.contributor.authorThuerlimann, Beat
dc.contributor.authorRegan, Meredith M.
dc.contributor.authorNeven, Patrick
dc.contributor.authorGiobbie-Hurder, Anita
dc.contributor.authorGoldhirsch, Aron
dc.contributor.authorEjlertsen, Bent
dc.contributor.authorCoates, Alan S.
dc.contributor.authorGelber, Richard D.
dc.contributor.authorPrice, Karen N.
dc.contributor.authorRabaglio, Manuela
dc.contributor.authorWardley, Andrew
dc.date.accessioned2022-02-18T10:11:37Z
dc.date.available2022-02-18T10:11:37Z
dc.date.issued2011
dc.identifier.citationRegan M. M. , Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., Forbes J. F. , Smith I., Lang I., Wardley A., et al., "Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up", LANCET ONCOLOGY, cilt.12, sa.12, ss.1101-1108, 2011
dc.identifier.issn1470-2045
dc.identifier.otherav_848bdbde-f50a-4c72-8447-29db0296d7ed
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/178755
dc.identifier.urihttps://doi.org/10.1016/s1470-2045(11)70270-4
dc.description.abstractBackground Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8.1 years median follow-up.
dc.language.isoeng
dc.subjectHealth Sciences
dc.subjectOncology
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up
dc.typeMakale
dc.relation.journalLANCET ONCOLOGY
dc.contributor.departmentHarvard University , ,
dc.identifier.volume12
dc.identifier.issue12
dc.identifier.startpage1101
dc.identifier.endpage1108
dc.contributor.firstauthorID3379100


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster